X

Trial Profile

A study of biomarkers that predict efficacy of or resistance to trastuzumab emtansine for patients with HER2-positive non-small cell lung cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 12 Jan 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab emtansine (Primary)
Indications Non-small cell lung cancer
Focus Pharmacodynamics

Most Recent Events

04 Dec 2017 Results published in the Journal of Thoracic Oncology
18 Oct 2017 Results (n=15) presented at the 18th World Conference on Lung Cancer.
18 Oct 2017 According to results presented at the 18th World Conference on Lung Cancer, study was early terminated due to the limited efficacy.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com